#USA #Pulsed Field Ablation #Del Medtech #Steven Mickelsen #Cardiff by the Sea

Del Medtech Launch: Expanding Pulsed Field Ablation Technology

On September 5, 2025, Dr. Steven Mickelsen, an esteemed electrophysiologist and a pioneer in Pulsed Field Ablation (PFA), announced the establishment of Del Medtech Inc. This innovative startup aims to extend the applications of minimally invasive ablation technology beyond cardiac care, ultimately addressing significant unmet medical needs across various therapeutic fields.

Del Medtech is on a mission to develop single-use ablation devices that promise to enhance efficiency and improve patient outcomes. The initial focus will be in gastroenterology, ENT (ear, nose, throat), men's and women's health, and oncology. In these areas, the company has identified market potentials that boast annual revenues ranging from $1.4 billion to $7.4 billion, with projected growth rates between 9% and 13%.

"Our goal is to set a new global standard for minimally invasive tissue ablation," emphasized Dr. Mickelsen. He remarked on the transformative impact PFA technologies have had in catheter ablation over the past five years and expressed confidence in applying these successful strategies to tackle long-standing challenges in other medical areas.

Dr. Mickelsen is scheduled to present Del Medtech's vision at the LSI Emerging Medtech Summit in London on September 8, at 3 PM. This summit is a gathering of global healthcare innovation leaders exploring the future of medical technology. In anticipation of the rapid evolution of ablation therapies, he noted, “Much like the recent surge of interest in PFA within electrophysiology, Del Medtech is positioned to lead the forthcoming wave in ablative technologies. We eagerly welcome investors and partners keen to be part of shaping the future of ablation.”

About Del Medtech Inc.

Founded in 2024, Del Medtech aims to revolutionize minimally invasive therapies through innovative techniques derived from pulsed field ablation technologies. With an initial focus on diverse healthcare areas, including gastroenterology, ENT, men’s and women’s health, and oncology, Del Medtech is dedicated to redefining patient care through efficient ablation techniques. The company appeals for partnerships and investments as it embarks on this transformative journey.

As Dr. Mickelsen stated, “Del Medtech is ready to spearhead significant advancements in ablation beyond the heart, reiterating our commitment to bettering patient experiences through innovation.” The establishment of Del Medtech signals a new chapter in medical device development, where the aim is not only to harness existing technologies but to innovate processes that lead to better healthcare outcomes.